Highlights and Quick Summary
- Average Receivables for the quarter ending September 30, 2022 was $34.4 Million (a -0.42% decrease compared to previous quarter)
- Year-over-year quarterly Average Receivables increased by 80.83%
- Annual Average Receivables for 2021 was $19 Million (a 23.6% increase from previous year)
- Annual Average Receivables for 2020 was $15.4 Million (a 16.46% increase from previous year)
- Annual Average Receivables for 2019 was $13.2 Million (a 153.98% increase from previous year)
Visit stockrow.com/BCRX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Average Receivables of BioCryst Pharmaceuticals, Inc.
Most recent Average Receivablesof BCRX including historical data for past 10 years.Interactive Chart of Average Receivables of BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. Average Receivables for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2022 | – | $34.41 | $34.56 | $27.4 | – |
2021 | $19.03 | $15.82 | $15.81 | $12.01 | $19.03 |
2020 | $15.4 | $4.51 | $3.8 | $5.32 | $15.4 |
2019 | $13.22 | $3.5 | $2.97 | $5.35 | $13.22 |
2018 | $5.21 | $6.19 | $2.83 | $7.63 | $5.21 |
2017 | $7.44 | $7.48 | $2.78 | $8.47 | $7.44 |
2016 | $7.51 | $6.73 | $3.27 | $6.49 | $7.51 |
2015 | $7.87 | $5.37 | $2.6 | $4.44 | $7.87 |
2014 | $5.8 | $2.8 | $0.96 | $3.8 | $5.8 |
2013 | $3.34 | $3.07 | $3.05 | $5.09 | $3.34 |
2012 | $5.2 | $7.7 | $10.52 | $15.96 | $5.2 |
Business Profile of BioCryst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology